Amgen (NASDAQ:AMGN) Posts Quarterly Earnings Results, Beats Estimates By $0.66 EPS

Amgen (NASDAQ:AMGN) posted its earnings results on Tuesday. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66, FiscalAI reports. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion.

Amgen Price Performance

Shares of AMGN stock traded down $4.19 during trading hours on Tuesday, hitting $461.26. 2,321,883 shares of the company’s stock were exchanged, compared to its average volume of 2,744,399. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market cap of $249.37 billion, a P/E ratio of 28.67, a P/E/G ratio of 3.31 and a beta of 0.41. The firm has a 50 day moving average of $420.49 and a two-hundred day moving average of $375.49. Amgen has a fifty-two week low of $294.48 and a fifty-two week high of $475.64.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a $2.52 dividend. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s payout ratio is 62.65%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 in the last three months. 0.85% of the stock is owned by corporate insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported third-quarter adjusted earnings of $6.45 per share, beating the $5.79 consensus estimate, while revenue of $10.37 billion also topped expectations of $10.07 billion. Amgen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Separate coverage highlighted data showing Amgen’s Imdelltra, combined with AstraZeneca’s Imfinzi, reduced the risk of death by 58% in patients with advanced lung cancer. The findings could support the drug’s growth potential, subject to further clinical and regulatory progress. Amgen Just Gave Its Shareholders Great News
• Negative Sentiment: An FDA warning letter over allegedly misleading promotion of Vectibix raises regulatory and reputational concerns, potentially offsetting some of the positive reaction to the earnings beat. Amgen Gets FDA Warning Letter Over Vectibix Promotion

Analyst Upgrades and Downgrades

AMGN has been the topic of several analyst reports. TD Cowen increased their price target on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Piper Sandler boosted their price objective on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Cantor Fitzgerald upped their target price on Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Guggenheim dropped their target price on Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a report on Tuesday, October 13th. Finally, Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Hold” and an average price target of $389.71.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.